Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Catalent (CTLT – Research Report), Moderna (MRNA – Research ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...